Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
AKBA's Cash to Debt is ranked higher than
72% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. AKBA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AKBA' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: 12424.6
Current: No Debt
N/A
12424.6
Interest Coverage No Debt
AKBA's Interest Coverage is ranked higher than
62% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AKBA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: -0.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -86.81
AKBA's ROE (%) is ranked lower than
76% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. AKBA: -86.81 )
Ranked among companies with meaningful ROE (%) only.
AKBA' s ROE (%) Range Over the Past 10 Years
Min: -86.81  Med: -51.66 Max: -51.66
Current: -86.81
-86.81
-51.66
ROA (%) -66.24
AKBA's ROA (%) is ranked lower than
77% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. AKBA: -66.24 )
Ranked among companies with meaningful ROA (%) only.
AKBA' s ROA (%) Range Over the Past 10 Years
Min: -365.24  Med: -61.1 Max: -47.82
Current: -66.24
-365.24
-47.82
ROC (Joel Greenblatt) (%) -9603.27
AKBA's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. AKBA: -9603.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKBA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -106220  Med: -31616.67 Max: -9603.27
Current: -9603.27
-106220
-9603.27
» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

AKBA Guru Trades in Q4 2015

Steven Cohen 42,000 sh (New)
Jim Simons 109,200 sh (-1.36%)
» More
Q1 2016

AKBA Guru Trades in Q1 2016

Paul Tudor Jones 18,498 sh (New)
Jim Simons 28,500 sh (-73.90%)
Steven Cohen 100 sh (-99.76%)
» More
Q2 2016

AKBA Guru Trades in Q2 2016

Paul Tudor Jones 18,798 sh (+1.62%)
Steven Cohen Sold Out
Jim Simons 24,300 sh (-14.74%)
» More
Q3 2016

AKBA Guru Trades in Q3 2016

Jim Simons 151,800 sh (+524.69%)
Paul Tudor Jones 18,410 sh (-2.06%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SPPI, NAS:SRNE, NAS:CRBP, NAS:CEMP, NAS:MESO, NAS:SVA, NAS:ADAP, NAS:FOMX, NAS:GERN, NAS:NVAX, NAS:OMED, NAS:LJPC, NAS:BSTC, NAS:EDGE, NAS:SYRS, NAS:IMMU, OTCPK:TYMI, NAS:CRVS, NAS:VYGR, AMEX:BTX » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.

Ratios

vs
industry
vs
history
P/B 3.22
AKBA's P/B is ranked higher than
54% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. AKBA: 3.22 )
Ranked among companies with meaningful P/B only.
AKBA' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.5
Current: 3.22
0
9.5
Current Ratio 6.32
AKBA's Current Ratio is ranked higher than
62% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. AKBA: 6.32 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 6.32  Med: 13.97 Max: 26.43
Current: 6.32
6.32
26.43
Quick Ratio 6.32
AKBA's Quick Ratio is ranked higher than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. AKBA: 6.32 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 6.32  Med: 13.97 Max: 26.43
Current: 6.32
6.32
26.43

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.53
AKBA's Price/Net Cash is ranked higher than
71% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. AKBA: 3.53 )
Ranked among companies with meaningful Price/Net Cash only.
AKBA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 2.49 Max: 4.71
Current: 3.53
2.02
4.71
Price/Net Current Asset Value 3.39
AKBA's Price/Net Current Asset Value is ranked higher than
71% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. AKBA: 3.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AKBA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.99  Med: 2.43 Max: 4.65
Current: 3.39
1.99
4.65
Price/Tangible Book 3.26
AKBA's Price/Tangible Book is ranked higher than
62% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. AKBA: 3.26 )
Ranked among companies with meaningful Price/Tangible Book only.
AKBA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.98  Med: 2.4 Max: 4.63
Current: 3.26
1.98
4.63
Earnings Yield (Greenblatt) (%) -67.58
AKBA's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. AKBA: -67.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKBA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -132.22  Med: 0 Max: 0
Current: -67.58
-132.22
0

More Statistics

EPS (TTM) $ -3.28
Short Percentage of Float7.03%
52-Week Range $7.00 - 13.20
Shares Outstanding (Mil)38.32

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 65 105
EPS ($) -3.57 -2.55 -2.36 -1.20
EPS w/o NRI ($) -3.57 -2.55 -2.36 -1.20
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
SHAREHOLDER ALERT: Sarraf Gentile LLP Announces Securities Class Action Lawsuit Against Akebia... Dec 07 2016
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Dec 02 2016
Akebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
AKEBIA THERAPEUTICS, INC. Financials Nov 17 2016
Coverage initiated on Akebia Therapeutics by Aegis Capital Nov 15 2016
Akebia Announces Third Quarter 2016 Financial Results Nov 09 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
Akebia Therapeutics reports 3Q loss Nov 09 2016
Akebia Therapeutics reports 3Q loss Nov 09 2016
Akebia Announces Third Quarter 2016 Financial Results Nov 09 2016
Akebia to Present at the Credit Suisse 25th Annual Healthcare Conference Oct 31 2016
Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2016... Oct 17 2016
Akebia Price Target Lowered, Still A Buy At Brean Sep 29 2016
Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with... Sep 26 2016
Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with... Sep 26 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Sep 20 2016
Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia... Sep 19 2016
Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia... Sep 19 2016
Akebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016 Sep 14 2016
Akebia to Present at Upcoming Investor Conferences Sep 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)